ReviewTaiwan journal of ophthalmology
Central serous chorioretinopathy: Pathophysiology, systemic associations, and a novel etiological classification.
Review in Taiwan journal of ophthalmology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 19 citations in OpenAlex.
- Systemic C-reactive protein levels and central serous chorioretinopathy: A systematic review with meta-analysis.Acta ophthalmologica · 2026Pooled it
- Beyond the vision: central serous chorioretinopathy, anxiety and depression-a systematic review.Frontiers in medicine · 2025Pooled it
- Klippel-Trenaunay syndrome presenting with bilateral chronic central serous chorioretinopathy: a case report.Journal of medical case reports · 2026Article
- Central Serous Chorioretinopathy Following Corticosteroid Injection for Thumb Carpometacarpal Osteoarthritis: A Case Report.Journal of orthopaedic case reports · 2026Article
- Global Incidence of Central Serous Chorioretinopathy: A Systematic Review, Meta-analysis, and Forecasting Study.Ophthalmology and therapy · 2025Article
- Sleep and mood in central serous chorioretinopathy.Eye (London, England) · 2025Article
- Quantitative Changes in Vascular and Neural Fibers Induced by Subretinal Fluid Excluding the Peripapillary Region in Patients with Chronic Central Serous Chorioretinopathy.Diagnostics (Basel, Switzerland) · 2025Article
- Influence of combined eplerenone, aflibercept and nepafenac therapy on central serous chorioretinopathy.International journal of ophthalmology · 2025Article
- Optical Coherence Tomography Study of Choroidal Response to Exercise-Induced Hypertension in Chronic Central Serous Chorioretinopathy.Journal of clinical medicine · 2024Article
- Increased oxidative stress biomarkers in central serous chorioretinopathy.Scientific reports · 2024Article
- The role of inflammation in central serous chorioretinopathy: From mechanisms to therapeutic prospects.Frontiers in pharmacology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Central serous chorioretinopathy (CSC) has remained an enigmatic disease since its initial description by Von Graefe. Over the years, multiple risk factors have been recognized: these include psychological stress, behavioral traits, and corticosteroids. The basic pathophysiology of CSC involves choroidal thickening, vascular congestion, altered choroidal blood flow (ChBF), and choroidal hyperpermeability, leading to retinal pigment epithelium decompensation and subsequent neurosensory detachment. Multiple organ systems, mainly the nervous, cardiovascular, endocrinal, and renal systems participate in the control of the vascular tone and the ChBF via hypothalamus-pituitary-adrenal axis and renin-angiotensin-aldosterone system, while others such as the hepatic system regulate the enzymatic degradation of corticosteroids. Many vasoactive and psychotropic drugs also modulate the ocular perfusion. In addition, there are anatomical and genetic predispositions that determine its progression to the chronic or recurrent form, through cellular response and angiogenesis. We herein review the basic pathophysiology and immunogenetics in CSC along with the role of multiple organ systems. With this background, we propose an etiological classification that should provide a framework for customized therapeutic interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.